EKTA-B Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Elekta Care, a personalized services for radiotherapy suites. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Elekta Geneva, an applicator for cervical cancer patients; and Elekta Xoft Axxent electronic brachytherapy systems. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning; Elekta Care Community, a self-help center; and Elekta Partner Community, an online self-service portal. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Elekta (STO: EKTA-B)
›
Elekta (STO: EKTA-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 3,996 employees.
The shares were at 62.00 SEK on 19 November 2026, up 32.5% over 52 weeks. Its 52-week range is 41.86 SEK to 66.70 SEK: the price is 7.0% below the high and 48.1% above the low.
Its market capitalisation is 23.69B SEK. It pays a dividend yielding 3.84%, against a median of 2.36% among the dividend payers in that peer group.
Elekta reports return on equity of -7.3%, an operating margin of 9.2% and revenue down 3.0% year over year.
Its debt exceeds its cash by 4.53B SEK, a debt-to-equity ratio of 1.03. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 15 analysts cover the stock, with an average rating of Hold; their mean price target of 59.05 SEK is 4.8% below the current price. The next earnings report is expected on 25 November 2026.